Skip to Content

Antisense Pharma With New Management Structure

REGENSBURG, Germany, December 19, 2007 /PRNewswire/ -- Antisense Pharma announced today that Dr. Reimar Schlingensiepen, Managing Director and cofounder, has stepped down as Chief Operating Officer effective 30.11.2007. He will remain a shareholder and will continue to support the company in an advisory capacity. Dr. Karl-Hermann Schlingensiepen, Chief Executive Officer, has now assumed sole leadership of Antisense Pharma.

In line with the strategic focus on market approval of its lead product, the management has transformed Antisense Pharma into a highly developed biotech company. The new leadership structure with a sole top-management is last but not least a consequence of the progressive internationalization, which will reach its present culmination in 2008 with the beginning of a Phase III clinical trial in glioma.

Dr. Reimar Schlingensiepen was Managing Director and Chief Operating Officer from 2002 to 2007 where amongst others he was responsible for all areas of Finance, Drug Manufacturing and Human Resources.

"My brother and I look back on a successful corporate history. Reimar has made significant and extraordinary contributions towards this prosperous development," said Dr. Karl-Hermann Schlingensiepen. In this context he successfully led the last round of financing securing EUR 27 million (USD 38 million) in November 2007. Dr. Karl-Hermann Schlingensiepen, Dr. Hubert Heinrichs (Chief Medical Officer), and the Board of Directors thank Dr. Reimar Schingensiepen for his outstanding accomplishments.

The managing directors have succeeded in establishing the business in a way that their scientific edge and unique technology has translated into a sophisticated product portfolio with the promising lead molecule AP12009. With the international Phase III-study in glioma, Antisense Pharma will rank among international key players in biopharmaceutical drug development

"I am very proud of what the colleagues at Antisense Pharma have accomplished for the benefit of patients and I look at future milestones with great confidence," recapitulates Dr. Reimar Schlingensiepen.

About Antisense Pharma GmbH

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. The agents specifically block the synthesis of key cancer proteins. The pipeline comprises products for high-grade glioma, pancreatic carcinoma, colorectal carcinoma, malignant melanoma, lung carcinoma and prostate carcinoma as well as other forms of cancer in different stages of clinical and preclinical development. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award.


This document contains forward-looking statements with respect to the future business of Antisense Pharma GmbH. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that could occur in the future. There is a number of factors that could cause actual results and developments to differ materially. Antisense Pharma GmbH disclaims any intent of obligation to update any of these forward-looking statements.


    Dr. Heike Specht / Public Relations

    Josef-Engert-Str. 9, D-93053 Regensburg

    Phone: +49-941-92013-0 / Fax: +49-941-92013-29


CONTACT: Contact: Dr. Heike Specht / Public Relations, Josef-Engert-Str.9, D-93053 Regensburg, Phone: +49-941-92013-0, Fax: +49-941-92013-29,e-mail:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: December 2007